BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 16699277)

  • 1. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care.
    Hollenz M; Stolte M; Leodolter A; Labenz J
    Dig Dis; 2006; 24(1-2):189-94. PubMed ID: 16699277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gastrointestinal complications under NSAID treatment in the doctor's office].
    Hollenz M; Labenz J
    MMW Fortschr Med; 2004 Dec; 146(49):42, 44. PubMed ID: 15646716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease.
    Voutilainen M; Mäntynen T; Färkkilä M; Juhola M; Sipponen P
    Scand J Gastroenterol; 2001 Aug; 36(8):817-21. PubMed ID: 11495076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong.
    Xia B; Xia HH; Ma CW; Wong KW; Fung FM; Hui CK; Chan CK; Chan AO; Lai KC; Yuen MF; Wong BC
    Aliment Pharmacol Ther; 2005 Aug; 22(3):243-9. PubMed ID: 16091062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A NSAID-associated alimentary tract disease in patients with rheumatism in Russia].
    Karataev AE; Konovalova NN; Litovshenko AA; Lomareva NI; Nemtsov BF; Raskina TA; Peshekhonova LK; Nasonov EL
    Klin Med (Mosk); 2005; 83(5):33-8. PubMed ID: 15984580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.
    Larkai EN; Smith JL; Lidsky MD; Graham DY
    Am J Gastroenterol; 1987 Nov; 82(11):1153-8. PubMed ID: 3499815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making.
    Hansen JM; Hallas J; Lauritsen JM; Bytzer P
    Scand J Gastroenterol; 1996 Feb; 31(2):126-30. PubMed ID: 8658033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
    Laine L
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use.
    al-Assi MT; Genta RM; Karttunen TJ; Graham DY
    Endoscopy; 1996 Feb; 28(2):229-33. PubMed ID: 8739738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury.
    Griffin MR
    Am J Med; 1998 Mar; 104(3A):23S-29S; discussion 41S-42S. PubMed ID: 9572317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsteroidal antiinflammatory drug-induced mucosal lesions of the upper gastrointestinal tract and their relationship to Helicobacter pylori.
    Rybár I; Masaryk P; Mateicka F; Kopecký S; Rovenský J
    Int J Clin Pharmacol Res; 2001; 21(3-4):119-25. PubMed ID: 12067141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
    Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
    Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe.
    Arroyo MT; Forne M; de Argila CM; Feu F; Arenas J; de la Vega J; Garrigues V; Mora F; Castro M; Bujanda L; Cosme A; Castiella A; Gisbert JP; Hervas A; Lanas A
    Helicobacter; 2004 Jun; 9(3):249-54. PubMed ID: 15165261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.